AUTHORS
Ilene Weitz, MD, Alexander Röth, MD2, Morie Gertz, MD3
AFFILIATIONS
1 Keck School of Medicine of Usc, Los Angeles, California, United States
2 Essen University Hospital Department of Neurosurgery, Essen, Germany
3 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia, recognized by international consensus guidelines as a distinct low-grade clonal B-cell lymphoproliferative disorder, and characterized by complement-mediated erythrocyte destruction, primarily through activation of the classical pathway. The resulting hemolysis leads to profound fatigue and episodic acute hemolytic exacerbations. Cold-induced circulatory symptoms (CICS) arise primarily from erythrocyte agglutination, also contributing to disease burden (Berentsen. Hematology Am Soc Hematol Educ Program; 2025(1):295–304).
Since publication of the 2020 consensus guidelines (Jäger et al. Blood Rev; 2020(41):100648), advances in the understanding of CAD biology and targeted therapies have reshaped the treatment landscape. These developments highlight the need for updated recommendations that integrate a disease mechanism-based treatment approach along with individualized patient management. This study aimed to update international CAD diagnosis and treatment guidelines through the development of consensus recommendations and treatment algorithm.
Methods
A Delphi consensus methodology was used (Diamond et al. J Clin Epidemiol; 2014;67(4):401–409), informed by a targeted literature review and an insights survey completed by a steering committee (SC) of three clinicians with expertise in CAD management. Key domains were subsequently identified, and consensus statements were developed, refined by the SC, and evaluated by an international panel of CAD experts. Agreement was assessed using a 6-point Likert scale, with consensus predefined as ≥75% of respondents selecting a “somewhat agree”, “agree”, or “strongly agree” response. Free-text feedback was collected when the respondent selected “strongly disagree”, “disagree”, or “somewhat disagree”. Statements with the highest levels of agreement were prioritized for inclusion in the final recommendations and treatment algorithm.
Results
Twenty-five hematologists from 21 academic and clinical institutions participated; most (84%) were from USA, had ≥5 years of CAD-specific experience (56% with >20 years), and managed >5 patients annually (76%). Fifty-four consensus statements across 6 domains were developed and evaluated: diagnosis (n=11), treatment initiation and selection (n=12), treatment efficacy and durability (n=5), thrombosis risk and thromboprophylaxis (n=5), long-term treatment adherence and discontinuation (n=16), and management of emergency events (n=5). Consensus was achieved for 51/54 statements (94%), with 46 (85%) reaching ≥90% agreement. Diagnosis-related statements achieving 100% agreement emphasized strategies to reduce missed or delayed diagnoses through improved clinician awareness, integration of CAD expert input, clinician–laboratory communication, and standardized diagnostic testing. Consensus recommendations support a treatment approach based on symptomatic disease, quality-of-life impact, and overall disease burden rather than hemoglobin level alone, with sutimlimab as first-line therapy for appropriate patients. Respondents agreed that in patients with severe CICS B-cell directed therapy is preferred, and biomarker-guided monitoring is recommended for ongoing management. Unanimous agreement was reached for the statement “time to response is generally much shorter with complement inhibitors compared with B-cell directed therapies”, and near-unanimous consensus was reached to recommend routine assessment of fatigue using a validated instrument such as the FACIT-Fatigue at each visit or, at minimum, every 6 months. Other statements reaching consensus addressed treatment safety, adherence considerations, and emergency care. Three statements did not reach consensus (44–72% agreement), with qualitative feedback indicating differing views on thromboprophylaxis criteria and treatment sequencing.
Conclusion
The Delphi process achieved high levels of agreement among an international panel of CAD experts, supporting updated, evidence-informed recommendations and a standardized treatment algorithm for diagnosis and treatment initiation based on overall clinical presentation. Long-term management of CAD should be guided by disease activity and biomarker response.
Funding statement: The authors thank the Delphi panel members for their participation. Triducive Partners Ltd provided facilitation of the Delphi process and medical writing support, which was funded by Recordati Rare Disease Inc.
DISCLOSURES
Ilene Weitz, MD: Recordati - Honoraria; Alexion - Honoraria; Novartis - Honoraria; AstraZeneca - Honoraria; Novartis - Research Funding; Recordati - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony)